Targeting Ferroptosis to Overcome Drug Resistance in Cancer:Molecular Mechanisms and Therapeutic Prospects
10.4062/biomolther.2025.211
- Author:
Sang Hoon JOO
1
;
Yong-Yeon CHO
;
Jung-Hyun SHIM
Author Information
1. College of Pharmacy, Daegu Catholic University, Gyeongsan 38430, Republic of Korea
- Publication Type:Invited Review
- From:Biomolecules & Therapeutics
2026;34(1):18-29
- CountryRepublic of Korea
- Language:English
-
Abstract:
Drug resistance in cancer cells remains a major obstacle limiting the clinical efficacy of current anticancer therapies. The induction of ferroptosis, an iron-dependent, regulated form of cell death, may offer an alternative therapeutic strategy to overcome such resistance. The generation of reactive oxygen species (ROS) has been implicated in this process, and depending on the cellular context, ROS can be either detrimental or beneficial. Ferroptosis can be effectively triggered in drug-resistant cancer cells in which ROS levels are often highly elevated. Key signaling pathways, including receptor tyrosine kinase (RTK), mitogen-activated protein kinase (MAPK), and nuclear factor erythroid 2-related factor 2 (NRF2), are promising targets for modulating ROS homeostasis and sensitizing cancer cells to ferroptosis. In this review, we discuss the molecular mechanisms governing ferroptosis, the interplay between ROS and ferroptosis resistance, and emerging therapeutic approaches designed to enhance ferroptosis induction in drug-resistant cancer cells. Altogether, a combination of ferroptosis inducers and conventional treatments may improve the therapeutic efficacy and help overcome resistance mechanisms.
